Keywords
Metformin
Obese T2DM
Research progress
Submitted : 2025-08-09
Accepted : 2025-08-24
Published : 2025-09-08
Abstract
In recent years, the incidence of type 2 diabetes mellitus (T2DM) caused by obesity in China has been increasing continuously, which has become a risk factor for the onset of T2DM and seriously affects the quality of life of patients. The conventional treatment methods include weight loss and regulating the body’s metabolism. Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1RA), mainly reduces patients’ appetite, decreases their craving for high-fat and high-sugar foods, regulates hypothalamic feeding behavior, inhibits gastric emptying and gastrointestinal motility, and ultimately leads to weight loss. Metformin mainly acts on extra-islet tissues, increasing glucose utilization, reducing glucose production, and ultimately lowering blood glucose levels. Based on this, this article reviews relevant literature on authoritative websites such as CNKI and Wanfang, organizes the data, and analyzes the research progress of semaglutide combined with metformin in the treatment of obese T2DM. The aim is to bring more treatment options for obese T2DM and promote better prognosis for patients.
References
Lu Y, Li M, 2025, Research Progress on the Treatment of Obese Polycystic Ovary Syndrome with Semaglutide Combined with Metformin. Advances in Clinical Medicine, 15(1): 534–537.
Ni W, You J, Feng X, 2023, A Case of Type 2 Diabetes Mellitus Complicated with Polycystic Ovary Syndrome Treated with Semaglutide Combined with Pioglitazone and Metformin. Chinese Journal of Diabetes Mellitus, 15(Z2): 181–184.
Guo R, Chen Y, 2024, A Case of Type 2 Diabetes Mellitus with Multiple Cardiovascular Risk Factors Treated with Semaglutide. Chinese Journal of Diabetes Mellitus, 16(Z2): 111–114.
Shams AH, Aziz MH, Kuraishy AMH, 2024, The Potential Effects of Metformin and/or Sitagliptin on Leptin/Adiponectin Ratio in Diabetic Obese Patients: A New Therapeutic Effect. JPMA. The Journal of the Pakistan Medical Association, 74(10 Suppl-8): S241–S245.
Díez G, Oliva L, Jiménez P, et al., 2024, Cocoa and Carob Supplementation, Alone or in Combination with Metformin, Protects Against Hepatorenal Injury in Zucker Diabetic Fatty Rats. Nutrients, 16(18): 3087–3087.
Wang H, Peng W, Liu Y, 2024, A Case of Type 2 Diabetes Mellitus Complicated with Acute Coronary Syndrome Treated with Semaglutide. Chinese Journal of Diabetes Mellitus, 16(Z2): 101–103.
Xu Z, Ao W, Huang T, et al., 2025, The Effect of Semaglutide Combined with Metformin in the Treatment of Obese Patients with Type 2 Diabetes Mellitus. China Kangfu Medicine, 37(7): 26–28, 36.
Ye Q, 2024, The Influence of Semaglutide Combined with Metformin on Glucose and Lipid Metabolism Indexes and Body Mass Index Levels in Obese Patients with Type 2 Diabetes Mellitus. Diabetes New World, 27(16): 121–124.
Shi W, Wang J, Liu Y, 2024, The Effect of Semaglutide Combined with Metformin in the Treatment of Obese Patients with Type 2 Diabetes Mellitus. China Kangfu Medicine, 36(1): 25–27.
Ye J, Chen D, Qiu Z, et al., 2024, Efficacy Analysis of Semaglutide Combined with Dapagliflozin and Metformin in Obese Patients with Type 2 Diabetes Mellitus Complicated with Nonalcoholic Fatty Liver Disease. Diabetes New World, 27(1): 19–22.
Xu S, Zhao Z, Zheng G, 2025, The Efficacy of Semaglutide Combined with Insulin in the Treatment of Obese Type 2 Diabetes and Its Impact on Patients’ Physical Indicators. Tianjin Pharmaceutical Journal, 37(4): 450–454.
Hu Z, 2025, The Effect of Dapagliflozin Combined with Semaglutide on Glucose and Lipid Metabolism in Obese Patients with Type 2 Diabetes. Modern Diagnosis and Treatment, 36(3): 389–391.
Yu M, Hu Y, 2024, Observation on the Clinical Effect of Dapagliflozin Combined with Semaglutide in the Treatment of Obese Type 2 Diabetes Patients. Tianjin Pharmaceutical Journal, 36(2): 55–58.
Li C, Chen P, Huang Q, et al., 2024, The Effect of Dapagliflozin Combined with Semaglutide in the Treatment of Obese Type 2 Diabetes and Its Impact on Glucose and Lipid Metabolism Indicators. Rational Drug Use in Clinic, 17(35): 28–31.
Ma Z, 2024, Observing the Effects of Semaglutide Combined with Metformin on Glucose and Lipid Metabolism and Body Weight in Obese Patients with Type 2 Diabetes. Modern Diagnosis and Treatment, 35(13): 1946–1948.
Xu X, Jin G, Han J, et al., 2023, Analysis of the Efficacy and Safety of Semaglutide in the Treatment of Overweight or Obese Type 2 Diabetes. Chinese Journal of Diabetes, 15(Z2): 35–39.
Liu Y, Ren J, Ren Z, et al., 2023, A Case of Semaglutide in the Treatment of Type 2 Diabetes with End-Stage Renal Disease. Chinese Journal of Diabetes, 15(Z2): 67–69.
Tan Q, Luo X, Chen Q, 2020, Evaluation of the Efficacy and Safety of Liraglutide Combined with Metformin in Obese Patients with Type 2 Diabetes Mellitus. Chinese and Foreign Medical Research, 18(36): 143–144.
Jiang L, Li J, 2022, The Efficacy of Orlistat Combined with Metformin in Obese Patients with Type 2 Diabetes and Its Impact on Body Mass Index, Beta-Cell Function Index, and Insulin Resistance Index. China Journal of Pharmaceutical Economics, 17(1): 71–74.
Chen Y, Lin X, Chen Y, 2022, The Effect of Dapagliflozin Combined with Metformin in the Treatment of Overweight and Obese Patients with Type 2 Diabetes Mellitus. Fujian Medical Journal, 44(6): 106–108.